Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 53Carcinoma, Hepatocellular 43Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 23Cholangiocarcinoma 22Urinary Bladder Neoplasms 21Colorectal Neoplasms 21Pancreatic Neoplasms 20Ovarian Neoplasms 17Triple Negative Breast Neoplasms 16Biliary Tract Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 12Neoplasms 11Carcinoma, Renal Cell 11Liver Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Uterine Cervical Neoplasms 7Esophageal Neoplasms 7Carcinoma, Squamous Cell 7Adenocarcinoma Of Esophagus 7Recurrence 6Prostatic Neoplasms 6Mesothelioma, Malignant 6Melanoma 6Gallbladder Neoplasms 6Fallopian Tube Neoplasms 6

Interventions

Nivolumab 3pembrolizumab 2durvalumab 2tremelimumab 1relatlimab 1lentiviral minigene vaccine of COVID-19 coronavirus 1fludarabine phosphate 1fludarabine 1bintrafusp alfa protein, human 1avelumab 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Specimen Handling 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Injections 1Immunoglobulin G 1High-Throughput Nucleotide Sequencing 1Educational Status 1Drug Therapy 1Disulfides 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Microsatellite Instability × durvalumab × Clear all
NCT04817826 2025-06-10

INFINITY

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting
31 enrolled
Gastrointestinal

Stomach Neoplasms, Microsatellite Instability

NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

Phase 2 Withdrawn

Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡